- letzte 200 News
- Archiv
| Zeit | Aktuelle Nachrichten | Rating | Leser | ||
|---|---|---|---|---|---|
| 09.09. | Martin Currie Global Portfolio Trust - Lower rates should be beneficial for performance | 239 | Martin Currie Global Portfolio Trust's (MNP's) performance was negatively affected in 2022 by the shift in interest rate expectations as US rates quickly moved up from 0.25% to 5.50%, in response to... ► Artikel lesen | ||
| 09.09. | Picton Property Income - Office repurposing progress | 148 | Picton Property Income's previously agreed sale of a vacated office building in Cardiff, to a purpose-built student accommodation developer, has taken a further step forward. A resolution to grant planning... ► Artikel lesen | ||
| 06.09. | OPAP - Improved momentum in Q224 | 713 | OPAP enjoyed improved momentum in Q224 driven by the ongoing innovation of its core products in both retail and online, and the anticipated boost from the UEFA European Football Championship 2024. Interestingly... ► Artikel lesen | ||
| 06.09. | EML Payments - Back to basics | 290 | EML Payments' FY24 results were the first to show the full impact of the liquidation of PFS Card Services Ireland Limited (PCSIL). Continuing operations, which exclude PCSIL, saw gross debit volume... ► Artikel lesen | ||
| 05.09. | IRLAB Therapeutics - New mesdopetam patent strengthens IP portfolio | 237 | IRLAB Therapeutics has been granted a new patent in Europe for its lead asset, Phase-III ready mesdopetam, which potentially extends its market exclusivity beyond the previous 2037 expiry. The updated... ► Artikel lesen | ||
| 05.09. | Argent Biopharma - An innovative approach to drug development | 297 | Argent BioPharma is a clinical-stage specialty biopharma company developing therapeutics targeting areas of unmet need. Currently focused on CNS conditions and immunology, Argent has a broad pipeline... ► Artikel lesen | ||
| 04.09. | Cereno Scientific - CS1 granted OMPD, complementing FDA ODD | 222 | Cereno Scientific's lead asset CS1 has been granted the Orphan Medicinal Product Designation (OMPD) from the European Commission as a potential treatment for pulmonary arterial hypertension (PAH). The... ► Artikel lesen | ||
| 03.09. | Georgia Capital - Business as usual despite political turmoil | 238 | Georgia Capital's (GCAP's) net asset value (NAV) per share decreased by 12.8% quarter-on-quarter in Q224 in Georgian lari (down 16.5% in sterling terms). This was mostly due to the widening of bond... ► Artikel lesen | ||
| 03.09. | Filtronic - Upgrading on follow-on space order | 243 | Filtronic continues to benefit from the agreement signed with SpaceX in April - it has received a follow-on production order for E-band solid state power amplifier (SSPA) modules with shipment expected... ► Artikel lesen | ||
| 03.09. | Impact Healthcare REIT - Visible growth | 204 | Impact Healthcare REIT continued to generate consistently positive accounting returns in the six months to June 2024 (5.5%), comprising fully covered DPS growth and increased NAV per share. With a clear... ► Artikel lesen | ||
| 02.09. | Nanoco Group - European partnership not moving forward | 281 | Nanoco Group's announcement that the collaboration with its European partner is essentially coming to an end is clearly disappointing news. We reduce our FY25 revenues by £2.5m and FY25 net cash by... ► Artikel lesen | ||
| 02.09. | Nabaltec - Increasing profitability and margins | 695 | Nabaltec recorded 2.2% y-o-y growth in its H124 revenue (€108.4m). The company's strong performance in its functional filler segment was the key driver of group revenue, up by 5.4% y-o-y (€78.2m). Its... ► Artikel lesen | ||
| 02.09. | Barton Gold - Special by name, special by nature | 881 | The publication of the results of its initial scoping study on the Tunkillia project on 16 July puts Barton well on the road to executing its three-phase development strategy to achieve c 150,000oz... ► Artikel lesen | ||
| 29.08. | Murray International Trust - Three become two - low-risk strategy maintained | 254 | Murray International Trust's (MYI's) managers Martin Connaghan and Samantha Fitzpatrick (the previous third manager Bruce Stout retired at the end of June 2024) are mindful that although markets were... ► Artikel lesen | ||
| 29.08. | CoinShares International - Resultatet från Q224formades av två engångshändelser | 306 | CoinShares International (CS) redovisade en stark justerad EBITDA under Q224 på 26,6 miljoner pund (jämfört med 11,4 miljoner pund under Q223), vilket inkluderade två engångsfaktorer: den fullständiga... ► Artikel lesen | ||
| 28.08. | Epwin Group - Robust H1 performance in tough markets | 242 | Epwin's H124 trading update confirmed that management expects to achieve full-year expectations despite market headwinds. Long-term, well-established growth trends imply that the company is well-placed... ► Artikel lesen | ||
| 28.08. | Basilea Pharmaceutica - EU paediatric approval triggers CHF10m milestone | 377 | Basilea has announced yet another milestone following the European Commission (EC) approval for Cresemba's use in the paediatric population (in invasive aspergillosis (IA) or mucormycosis (IM)). The... ► Artikel lesen | ||
| 27.08. | Actinogen Medical - Further positive XanaCIDD results on depression | 254 | New data were revealed from Actinogen Medical's ongoing analysis of the now-completed XanaCIDD study that support the view that the company's lead drug candidate, Xanamem, may provide consistent and... ► Artikel lesen | ||
| 27.08. | Mendus - Broad progress across the pipeline | 186 | Mendus's Q224 results reflect a period of steady progress across its clinical programmes. For vididencel, the Phase II CADENCE trial (for acute myeloid leukaemia, AML) is now ready to commence patient... ► Artikel lesen | ||
| 23.08. | Zalaris - Tenth consecutive quarter of revenue growth | 221 | Zalaris delivered a tenth consecutive quarter of year-on-year revenue growth in Q224 to another record of NOK323m. The company continued to win new business as well as renegotiating contracts with existing... ► Artikel lesen | ||
| 23.08. | CoinShares International - Q224 results shaped by two one-time events | 322 | CoinShares International (CS) posted a strong adjusted EBITDA in Q224 of £26.6m (vs £11.4m in Q223), which included two one-off factors: the £21.8m full write-down of its holdings in FlowBank and a... ► Artikel lesen | ||
| 23.08. | SIGA Technologies - TPOXX chalks up another DoD contract win | 377 | SIGA Technologies announced another contract win with the US Department of Defense (DoD), which is for the procurement of c $9m in TPOXX. This is the third DoD contract win in roughly three years for... ► Artikel lesen | ||
| 22.08. | Topps Tiles - Acquisition of well-respected competitor | 314 | The acquisition of certain assets of CTD Tiles (CTD) brings complementary activities to Topps Tiles' (TPT's) existing Omnichannel and Commercial businesses. Management believes these will enable faster... ► Artikel lesen | ||
| 22.08. | Actinogen Medical - XanaCIDD data narrow the focus in depression | 232 | While the results from Actinogen's XanaCIDD exploratory Phase IIa study in patients with major depressive disorder (MDD) did not meet the primary endpoint in terms of improving cognitive impairment... ► Artikel lesen | ||
| 22.08. | Basilea Pharmaceutica - Another Cresemba milestone payment in the bank | 273 | The uptrend in Cresemba sales in Asia-Pacific and China triggered the receipt of Basilea's third milestone payment of US$1.25m from Pfizer for the region (in addition to the March and May 2024 milestones).... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
